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Background: Academic literature and international standards bodies suggest that user involvement, via the
incorporation of human factors engineering methods within the medical device design and development (MDDD)
process, offer many benefits that enable the development of safer and more usable medical devices that are better
suited to users’ needs. However, little research has been carried out to explore medical device manufacturers’
beliefs and attitudes towards user involvement within this process, or indeed what value they believe can be
added by doing so.
Methods: In-depth interviews with representatives from 11 medical device manufacturers are carried out. We ask
them to specify who they believe the intended users of the device to be, who they consult to inform the MDDD
process, what role they believe the user plays within this process, and what value (if any) they believe users add.
Thematic analysis is used to analyse the fully transcribed interview data, to gain insight into medical device
manufacturers’ beliefs and attitudes towards user involvement within the MDDD process.
Results: A number of high-level themes emerged, relating who the user is perceived to be, the methods used, the
perceived value and barriers to user involvement, and the nature of user contributions. The findings reveal that
despite standards agencies and academic literature offering strong support for the employment formal methods,
manufacturers are still hesitant due to a range of factors including: perceived barriers to obtaining ethical approval;
the speed at which such activity may be carried out; the belief that there is no need given the ‘all-knowing’ nature
of senior health care staff and clinical champions; a belief that effective results are achievable by consulting a
minimal number of champions. Furthermore, less senior health care practitioners and patients were rarely seen as
being able to provide valuable input into the process.
Conclusions: Medical device manufacturers often do not see the benefit of employing formal human factors
engineering methods within the MDDD process. Research is required to better understand the day-to-day
requirements of manufacturers within this sector. The development of new or adapted methods may be required
if user involvement is to be fully realised.
Background
From a human factors engineering perspective, ensuring
the development of high quality and well designed med-
ical devices that are in tune with patient and user needs,
require formal human factors engineering methods (also
known as user-centred usability engineering methods) to
be used at every stage of the MDDD process [1].
Employing such formal methods ensures that the device
design process considers appropriately the environment
in which the device is to be used, the work patterns of
users and the specific individual needs of the user,
which could be any individual involved in the use of the
device including health professionals, patients, and lay
care givers [2]. In particular, human factors engineering
methods highlight the importance of considering the
needs of the user when designing and developing
devices at the earliest stage of defining the device con-
cept and then at every subsequent stage of the device
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focusing on user needs has been recognised as having a
number of health related benefits including; improved
patient safety [4,5], improved compliance and health
outcomes [6], and higher levels of patient and user satis-
faction [7]. Furthermore, employing human factors engi-
neering methods throughout the MDDD process has
been said to substantially reduce device development
time because usability issues are identified and attended
to prior launch, and hence avoid costly design changes
and product recalls [8,9].
Given the proposed benefits of developing medical
devices according to a human factors engineering per-
spective, medical device standards bodies are increas-
ingly recognising the importance of these methods and
the important role they play in developing safe and
usable medical devices. Currently the two most impor-
tant regulations for medical device developers are the
European Commission (EC) Medical Device Directive
93/42/EEC [10] and the United States (US) Food and
Drug Administration (FDA) regulations since medical
devices must comply with these regulations in order to
be sold throughout Europe and the US [11]. These regu-
lations promote the use of human factors engineering
methods within the MDDD process, for example, the
US FDA regulations specify that medical device develo-
pers must demonstrate that human factors principles
have been used in the design of the device so as to
ensure that use-related hazards have been identified,
understood and addressed. Some guidance is also given
suggesting how human factors principles may be inte-
grated into the MDDD process [12]. A further standard
that medical device developers have been obliged to
adhere in recent years is the International Electrotechni-
cal Commission (IEC) standard 60601-1-6 [13], which
have equivalent European Standards (ES) and British
Standards (BS), requiring medical device developers to
incorporate human factors engineering processes to
ensure patient safety, stating that “The manufacturer
should conduct iterative design and development.
Usability engineering should begin early and continue
through the equipment design and development life-
cycle”. More recently, the usability standard ‘IEC 62366:
Medical devices - Application of usability engineering to
medical devices’ [14] has superseded IEC 60601-1-6, and
extends the requirement for medical device developers
to incorporate human factors engineering methods in
the development of all medical devices, not just electri-
cal devices. In early 2010 IEC 62366 was harmonised by
the EU Medical Device Directive meaning that it is now
a legal requirement for medical device developers to for-
m a l l ya d d r e s st h eu s a b i l i t yo fad e v i c eb e f o r ep l a c i n gi t
on the market anywhere in Europe. In order to comply
with this standard, medical device developers must
document the process in detail within a Usability Engi-
neering File.
Human Factors Engineering Methods
The MDDD process may be considered to be made up
of four key stages. At stage one, user needs are estab-
lished and scoping exercises are carried out with users.
Stage two aims to validate and refine the concept. Stage
three involves designing the device, and Stage four
involved evaluation of the device.
Figure 1 presents the medical device development life-
cycle, and the associated user-centred design methods
that may be used at each respective stage.
In some of our earlier work, as part of the Multidisci-
plinary Assessment of Technology Centre for Healthcare
(MATCH) research activity, we carried out a rigorous
review of the methods that have been employed in the
MDDD process as presented in the academic literature
[5,11,15]. MATCH is a UK research initiative between
five universities which is funded by the Engineering and
Physical Sciences Research Council (EPSRC) and the
Department of Trade and Industry (DTI). The aim of
MATCH is to provide support to the healthcare sector
by developing methods to assess the value of medical
devices at every stage of the MDDD process, with a
focus on working with industrial partners to solve real
world problems.
To provide some insight into what a selection of these
methods involve, a brief description of the most fre-
quently occurring methods within the device develop-
ment lifecycle are now provided. For a detailed
description of all methods and how these may be
applied within the MDDD is provided in [5].
Focus groups involve group discussion typically
between 8-10 users, with a moderator guiding and facili-
tating the group through relevant topics of discussion.
They may be appropriate for use at stage one, two or
f o u ro ft h ed e v i c ed e v e l o p m e nt lifecycle. Focus groups
are used in a wide variety of industry settings and may
be conducted at a comparatively low cost compared
with other methods such as usability testing.
Interviews are one of the most common approaches
employed in user centred research, and may be of value
at stages one, two and four of the development pathway.
They can be rapidly deployed, and are relatively inex-
pensive to carry out. Interviews enable the researcher to
access a broad range of opinion regarding a device,
whilst also allowing rich and detailed opinions to be
collected.
Usability testing, typically performed at stage four,
advocates is a function of three criteria: effectiveness,
efficiency and satisfaction. Usability testing protocols
involve users carrying out specific tasks with a specific
device, whilst usability measures are taken. Effectiveness
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fully accomplish a given task. Efficiency may include a
count of the number of user actions or the amount of
time required to carry out a task. Satisfaction may typi-
cally be measured subjectively by means of a satisfaction
questionnaire, completed after using a particular device.
Heuristic evaluation is a more rapid form of usability
test which may be deployed by developers, perhaps
prior to carrying out usability tests. Developers step
through the device features and functionality and check
the extent to which it complies with pre-determined list
of characteristics (heuristics/rules of thumb) that may
have been defined by earlier UCD design activities. This
type of evaluation would normally be applied at stage
four of the development pathway, once a tangible device
has been developed.
The challenge for industry
Although a large number of human factors engineering
methods are available that may be employed within the
MDDD process, previous research indicates that medical
device manufacturers often avoid employing such meth-
ods due to lack of resources and the perception that
such methods are often too resource intensive [16]. The
literature in the area of user involvement suggests that
there are a number of risks for manufacturers associate
with a lack of engagement with users within the product
development process. For example, Cooper [17] suggests
that failure to build in the voice of the customer is one
of the key reasons for the failure of developing effective
and innovative products. Certainly in the realm of ICT
products Kujala [18] suggests that attending to user per-
spectives increase the likelihood of a successful product.
Alongside this however, other work has highlighted
some of the challenges of, and barriers to, involving
users in the product development process. Brown [19]
and Butler [20] both suggest that the volume of data
generated by field studies with users may be costly, diffi-
cult to analyse with no obvious route to informing
development. When considering the factors leading to
successful innovation, van der Panne et al. [21] note
that although it is incontrovertible that good market
research is associated with a successful product, the role
of customer involvement in innovation remains conten-
tious. They suggest that customer involvement at an
early stage may tend to gravitate towards imitative pro-
ducts, being less able to envision or express novelty and
thus, “bias innovation efforts towards incremental inno-
vation” [[21] p.326]. User preferences may change over
time and engaging with a limited range of users may
result in over specification of the product [22]. From the
developer’s perspective, their criteria for the success of
user involvement may be different than those (often aca-
demics or researchers) who actually do user engagement
work [23,24]. Furthermore, user information that is
based on formal methods of elicitation may be at var-
iance with the representations of the user held by devel-
opers themselves [22] and may thus not readily be
appropriated within the organisational culture and struc-
ture of the lead organisation [25]. Many of the above
examples are drawn from the more general area of user
involvement within the product development process,
since there is limited research in this area specifically
addressing such issues within the medical device devel-
opment domain. There is a lack of existing primary
research that explores the challenges and benefits of
involving users specifically within the medical device
development process, particularly from a medical device
manufacturer’s perspective. Examples of some of the
work that does exist within this domain includes, Gro-
cott et al. [26] who carry out pioneering work in the
field, proposing a valuable model of user engagement in
medical device development, and focus on the practical
issues around how user needs may be captured through-
out the MDDD process [26]. Shah and Robinson [16]
carry out secondary research in the form of a literature
review of research that has involved users in some way
in the design and development of medical devices,
exploring the barriers and benefits to involving users as
may have been reported in the reviewed literature.
Figure 1 Medical device development lifecycle adapted from [5].
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t i v eo f f e r e da b o v et h a tw h i l s tu s e ri n v o l v e m e n ti n
MDDD process is likely to benefit the user in terms of
developing devices better suited to the users’ needs,
MDDD methods may be perceived as highly resource
intensive and hence often not a feasible option for some
manufacturers.
Reflecting on the body of literature above, and in par-
ticular on the perceived benefits and barriers to user
involvement within the wider domain of technology pro-
duct development, it seems that there are a number of
key factors that impact on effective engagement with
users. Perhaps most notable is the notion that product
developers consider user needs research to be dispro-
portionately costly, in light of the perceived benefits and
pay-off for engaging in such activities. Furthermore, user
needs research is perceived by developers to generate
unmanageable volumes of data and there does not
appear to be any clear route through to informing the
development of the product once the user needs data
has been collected and analysed. Whilst all of the per-
ceived drawbacks, if well-founded, may be notable rea-
sons for avoiding engagement with user needs research,
it is not clear what the underlying reasons are for these
factors. For example, a commonly held view by some
developers is that the key function of human factors
engineering methods is to serve as a means of facilitat-
ing a ‘cake-frosting’ exercise [27], by which ‘superficial’
design features may be ‘painted’ onto the device at the
end of the development process. Such views of human
factors engineering methods do not lend themselves to
positive engagement or indeed a realisation of the full
complexity and pay-off that such methods may poten-
tially deliver if they were to be deployed with methodo-
logical rigour at appropriate points within the design
process [28]. Certainly from an academic and/or human
factors engineer’s point of view, it may be argued that
many of these factors may be overcome by increased
awareness and better educating industrial developers in
human factors engineering methods and their applica-
tion. However, is it the case that with more training in
the area of user research methods research, product
developers may overcome these reservations, recognise
the potential opportunities these methods promise, and
develop the necessary skills to deploy methods and ana-
l y s ed a t ai nat i m e l yf a s h i o n ,o ra r et h e s em e t h o d s
indeed incompatible within the industrial context?
Should user needs research be outsourced and delivered
by the human factors engineering experts, in order to
overcome the overhead in acquiring appropriate skills
and level of understanding to actually effectively deploy
these methods? Should these methods be adapted to
make them more lightweight and easier to implement,
hence making them more fit for purpose? These are all
questions that need to be answered if the goal of incor-
porating the user into the product development process
is to be realised. More specifically within the MDDD
p r o c e s s ,t h e r ea r el i k e l yt ob ed o m a i ns p e c i f i cf a c t o r s
and conditions that influence the uptake of such
methods.
Therefore, from a theoretical perspective, human fac-
tors engineering methods are presented as being of
value at every stage of the MDDD process, manufac-
turers may not actually be employing these methods in
practice. If their full benefits are to be realised, more
primary research is needed to better understand manu-
facturers’ perspectives and motivations regarding such
methods. Therefore, the aim of this study is to gain first
hand and detailed insights into what medical device
manufacturers’ attitudes are towards engaging with
users, and what the perceived value and barriers are of
doing so. Furthermore, we aim to explore which meth-
ods are used, and what device manufacturers’ attitudes
are towards employing such methods.
Section summary
Thus far, we have detailed a range of formal methods
that may be used to elicit user perspectives as part of
the process of medical device development and noted
the range of regulatory requirements to involve users.
We have suggested that the ‘in principle’ value of sys-
tematically seeking user input may be somewhat at var-
iance with the day to day experiences of manufacturers
where user involvement may be seen as a barrier to
speedy and innovative product development. There is
currently no evidence about this in respect of medical
device development. The remainder of this paper
addresses this issue and is structured as follows. In the
next section, we describe a study which involved carry-
ing out in-depth interviews with 11 medical device man-
ufacturers which explored the perceived value of users
in the MDDD process. In the following section, the
results of the analysis of these interviews are then pre-
sented. The paper concludes with suggested recommen-
dations for future research and practice in this area.
Methods
Eleven interviews were carried out with senior members
of staff in each company. Recruitment was by conveni-
ence sampling: participants were identified as a result of
their employment by companies that were industrial
partners of the MATCH collaboration. To provide case
examples for discussion, company representatives were
asked to choose one medical device to discuss during
the interview, which provided an example of the MDDD
process they engaged in. The majority of the devices
chosen for discussion were intended for use by surgeons
within a clinical setting. Interviews lasted approximately
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of the MATCH research team. One of the topics of dis-
cussion was around device users. Interviewees were
asked about the role the user is perceived to play within
the design and development of the example medical
device, what they saw as the barriers and benefits to
involving users within the MDDD process, and what
human factors engineering methods they used (if any)
within the MDDD process. All interviews were recorded
and researchers also took notes during the interviews.
Before beginning, the interviewer explained the purpose
and format of the interview to the participant and
informed consent to participate, and for the audio
recording of the interview, was obtained. Table 1 sum-
marises the position held within the company for each
interviewee, the treatment area or clinical use for the
device, the intended users of the devices, and the actual
individuals consulted in the MDDD process by the
respective manufacturers.
A thematic analysis of the textual dataset was then
carried out. Detailed descriptions of what the thematic
analysis process involves are available in [29-32]. In
brief, thematic analysis facilitates the effective and rigor-
ous abstraction of salient themes and sub-themes from
a complex and detailed textual dataset [33], hence is
particularly suitable in this context. The following steps
were taken to analyse the data collected during the
interview process, Figure 2 provides an overview of this.
Initially all recordings of the trial sessions were tran-
scribed into text format. After transcription, the textual
dataset was initially perused to conceptualise the over-
arching themes that existed within the transcripts at a
high-level. These were noted in a coding frame, with
each concept assigned a code name, and a description
and examples of text that fit each concept. The dataset
was then examined iteratively, enabling themes and sub-
themes to be developed further. These were spliced and
linked together, and text relating to each category and
sub-category were appropriately labelled. The first and
second authors coded the data and discussed inconsis-
tencies where these arose until a clear consensus of the
main themes was reached. When no further refinement
of the categorisation could be derived a final group of
categories and sub-categories, representative of the tran-
scripts was produced. The main themes are those drawn
from multiple contributions and that represent issues
that are clearly central to the participants themselves.
Within these themes, we have explored areas of consen-
sus and diversity as they were presented by interviewees.
Results
As a result of carrying out a thematic analysis of the
interviews carried out with manufacturers, four high
level themes emerged relating to manufacturers’ views
of user involvement within the MDDD process. These
are as follows: Who is the user?; Methods used; Per-
ceived value and barriers to user involvement; The nat-
ure of user contributions. The remainder of this section
presents the findings of our study according to these
themes.
Who is the User?
Discussions relating to the range of individuals that are
consulted during the MDDD process revealed that there
was a mismatch between the users that were consulted,
and those that would actually use the device in practice.
Table 1 Company details and intended device users
Position held Device’s treatment area or
clinical use
Intended users Individuals consulted
#1 Operations Mgr & Clin. Affairs Mgr. Orthopaedics Surgeons Surgeons
#2 Operations Mgr Cardiology Health profs. General
public
Health profs.
#3 Scientific Director Oncology Health profs. Physicians Health profs. Trainee health
professionals
#4 Director Spectroscopy Health profs. Clinicians Electronics experts
#5 Director of Clin. Research & Clin.
Reimbursement Mgr.
Orthopaedics Surgeons Surgeons
#6 Managing Director Orthopaedics Surgeons Surgeons
#7 R&D Mgr. Orthopaedics Surgeons Surgeons
#8 R&D Director Laryngology Gen. health practitioners Purchasing reps. Clinical
champion
#9 Managing Director Phlebotomy Clinicians University
researchers
Clinicians University researchers
#10 Medical Tech. Mgr. Vital signs monitoring Nurses Clinicians Physicians
#11 Research Programme Mgr. Wound care Home patients Surgeons
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patient do not originate from the patient themselves,
and that patients’ needs are better articulated through a
hierarchy of health professionals including surgeons and
‘clinical champions’.
#2: “The need actually will probably be established
by the clinical fraternity....All you have to do after
that is convince the people on down the chain, from
the hospital clinical researchers right down to the guy
in the street who says ‘It’s a good idea to have one of
these. That’s where the need is identified. It is identi-
fied really at the top, and then it’s taught down, if
you follow me”
In light of this, manufacturers had a preference for
seeking input from more senior health care staff over
less senior staff, regardless of who would actually use
the device in practice. The assumption was that senior
staff members were more than capable of speaking on
behalf of less senior staff, even though manufacturers
acknowledged that it was likely that senior staff mem-
bers would never actually use the device. This was the
case even in scenarios where the patient was seen to be
the main user of the device. For example, Manufacturer
#2 who is involved in the development of Automated
External Defibrillators (AEDs), recognised that a signifi-
cant proportion of the intended users of the device
included members of the public, however, they did not
see it as necessary to consult members of the public,
but rather consulted senior health professionals in the
early stages of device design and development. Input
from nurses was also considered to be less desirable
than input from more senior health care staff such as
surgeons. For example, Manufacturer #11 identified
nurses as the main user of their product, however, did
not consider it necessary to consult nurses in the design
and development process. It was felt that surgeons
made the decisions on behalf of nurses and patients,
and therefore it was logical to consult them to identify
nurse and patient needs, as is articulated below.
#11: “Surgeons may be there making the decision or
recommending which models to buy, but it might be
the nurses who are actually using the unit...the sur-
geon has made the decision, but he doesn’t necessa-
rily have to actually work with it, so in your case, the
controllability aspect, the patient actually under-
standing how to operate the unit, the clinician has
made the decision and has prescribed that particular
device...”
Surgeons were also considered by Manufacturer #11
as having sufficient knowledge to act as representatives
for home patients. The motivation for this was as a
direct result of the way in which the device is intro-
duced and promoted to the patient. Surgeons do the
marketing and promoting of the product to the patients,
and therefore it was seen as important that the device is
primarily designed according to the surgeons’ require-
ments. In the quote below, manufacturer #11 justifies
their motivation for valuing the surgeons’ opinion over
the patient users.
#11: “but, by and large, most of our market research
is done with the surgeons, not with the end users,
rightly or wrongly...but how it will be marketed will
be through the healthcare professional, who will have
Figure 2 Process of thematic analysis.
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use it.”
Similarly, in the event of the user group being general
health professionals, the opinions of a small number of
‘clinical champions’ was sought by Manufacturer #8 as
well as purchasing representatives from the health
authority. It was deemed more important to meet the
needs of the individuals who were responsible for mak-
ing purchasing decisions or held most influence over
them, as opposed to focusing on the needs of the indivi-
duals that would be using the devices on a day to day
basis. Therefore MDDD activity often seemed to be car-
ried out a strong focus on how effort would translate to
sales. In the following quote, Manufacturer #4 is asked
who would be consulted in identifying design require-
ments for the development of the given medical device:
#4: P
1: “...it’s through the doctors to, its [name]’s con-
tact with the hospitals out there, now then I doubt it
would be at doctor level, it would be more the man-
agerial level of the hospital...”
I




1 P: Denotes the participant’sr e s p o n s e ,
2 I:
Denotes the interviewer’s questioning)
Manufacturer #1 also focuses on those making/influ-
encing purchasing decisions, which includes manage-
ment and administrative staff. Manufacturer #1
articulates this shift in focus when asked who they view
as their customer:
#1: “Orthopaedic surgeons really. Although it is used
in patients, it is the orthopaedic surgeons who decide
what he will use. Sell to orthopaedic surgeons.
Increasingly in the UK, we have to sell to the hospital
management to justify why they should be using our
bone graft substitutes as opposed to any other on the
market...”
Manufacturer #8 stated that health professionals are
considered to be the main user of their device, However,
the opinions of purchasing representatives are the pri-
mary source used to inform device design and develop-
ment, followed up by consultation with a small number
of ‘clinical champions’ (typically high profile surgeons
and well known experts in their field). When questioned
o nw h a tv a l u et h eu s e rm a ya d dv a l u et ot h eM D D D
process, although couched in a humorous reply, it was
clear that the usefulness of the user was ideally directly
located in relation to sales relevant information.
#8: “The most helpful would to give me the year
three sales figures with absolute confidence. Year-1...
[laughs]...”
There seems to be limited overlap between the indivi-
duals that will be using the device, and those that are
consulted to inform the MDDD process. In particular,
priority is given to those that hold more senior positions
within the health care system. Therefore, surgeons, doc-
tors and clinical champions were seen as more valuable
sources for identifying user needs as opposed to those
individual that would actually use the device on a daily
basis. Furthermore, from the manufacturers’ point of
view, the motivation for maximising sales seems to have
conflated the distinction between the customer and the
user. Therefore the needs of those that make purchasing
decisions or indeed have most influence over these deci-
sions are more salient than the needs of the user. This
is certainly a more complex picture than the human fac-
tors engineering approach, which puts the user’sn e e d s
at the centre of the design and development process.
Methods used
Given the wide range of formal methods that are avail-
able to engage with users in the MDDD process, manu-
facturers tended to use only a very limited range of
methods to capture information from users and patients.
In line with the analysis above regarding the nature of
the preferred user to consult, the most typical method
used to gain input from users was via informal discus-
sions with senior health professionals. Only one out of
the eleven manufacturers (Manufacturer #8) stated that
they regularly used some formal methods throughout
the MDDD process, such as focus groups and question-
naires when developing their airway management device.
Interestingly, the initial identification of a need for this
device occurred as a resulto fs i xm e m b e r so ft h ec o m -
pany attending a postgraduate university course, which
required the use of formal methods in order to explore
and identify new device ideas. It was apparent that man-
ufacturers do not feel that they have the time or
resources to engage in rigorous formal user data collec-
tion methods, instead relying on a range of strategies
including gut feel, instinct, and a personal belief that
they understand the market place in which they operate,
in order to identify and develop new devices.
The idea of employing formal methods is once again
something that is not regarded as feasible, given the
amount of resources available and the fact that manu-
facturers believe it is necessary to move quickly in order
to remain competitive with their rivals. The view is that
consulting a large number of individuals is problematic
in itself, as every person that is approached for feedback
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as offering versatile and rapid solutions, hence the belief
that relying on gut feel and pressing ahead when the
moment feels right is a more feasible and efficient solu-
tion. This point is articulated by Manufacturer #8 below:
#8: “The very fact that someone is willing to talk
with you almost means that they have slightly differ-
ent view. You can go on asking forever. It’s that bal-
ance between have we got sufficient confidence in
what we have here to move forward vs. just the gen-
eration of the information....being confident enough of
its assurance. That’s what you constantly face any-
how. I think that’s the dilemma you always have.
You can ask the users till the cows come home but
you never get a new product. You ask 100,000 you
get 99,999 different opinions!”
Manufacturer #3 further echoes the observation that
formal methods are rarely used for medical device devel-
opment, however, informal discussions and observation
are seen as more versatile and fit for purpose, :
#3: P:"you’re introducing a medical device to people,
first question they’ll ask, is “what will it do to help
me?” Second question will be “how long is this going
to take?” In a busy clinic that’s really important...If it
takes too many clicks, then people won’tu s ei t
because they are busy enough as it is.”
I: have you been able to capture that at all?
P: “Through our interaction with users. We haven’t
got a specific mechanism for capturing it.”
I: Do you use any formal methods for converting cus-
tomer needs into product development?
P: “No.”
There was typically the belief that there was little need
to consult the actual users formally regarding a new
innovation, but rather contacting what they referred to
as a ‘clinical champion’, was sufficient to qualify the fea-
sibility and validity of a given new innovation. For
example, Manufacturer #8, responding to a question
regarding how the feasibility of new device ideas are
qualified responded:
#8: “Every project will have a clinical champion.
They will typically be involved, sometimes they come
down here to meetings. We have a list of a couple of
dozen clinicians that I can pick the phone up at any-
time throughout the world and say “what do you
think of this?”.
When asked whether there are any formal methods
used within their organisation, Manufacturer #6 stated
that formal methods are used within his organisation,
however, they are not relevant for this particular pro-
duct. Once again, formal methods, in this case example,
were considered to be too bureaucratic, time consum-
ing, and not applicable given the device and develop-
ment scenario. Informal methods, such as ad hoc
discussions with senior health professionals were likely
to identify the majority of user design needs, and were
also more appropriate.
#6:”Yes we do, but I couldn’t apply that to hip repla-
cement at this point in time. If the surgeon tells me
“that this catheter is a bit too stiff, and could you
make it a bit softer, if you like, or a bit more flexible,
yet do exactly the same task?” we will do that - it’s
for everyone’s benefit”
In the above example, a pragmatic approach is taken
by manufacturers to make modifications to devices,
adopting the belief that if a problem is encountered by
one individual, then it is likely to be a problem for the
majority, providing it seems to be a reasonable request.
The intuition of the manufacturer plays a major part in
the process of developing products that are useful to the
user, and responding to their needs.
Perceived value and barriers to user involvement
There was limited evidence that direct elicitation of user
views was seen by manufacturers as being of value to
the MDDD process. This appeared to be particularly the
case in relation to patient users. For example, Manufac-
turer #11, discussing their device that was purely aimed
at the home patient market, did not believe that patient
involvement in the MDDD process was a particularly
wise expenditure of resources. This was explicitly linked
to the degree of influence that they have in terms of the
level of power and influence they have in the levels of
uptake of the device. In response to being asked
whether they would like to involve the patient more in
the MDDD process, manufacturer #11 replied:
#11: “if they are highly powered (i.e. influential in
terms of clinical decision making), if they have no
power then we have to ethically try to make sure
that we don’t harm the patient and [that] what we
do is for their benefit, but appealing to them may
actually be a waste of resources, so we have to make
sure we don’t pretend that they have a sway when
they really don’t, you know? “
Once again, the above statement reinforces the notion
that patients are seen as being at the bottom of the hier-
archy of influence, and hence investing resources and
effort to find out their opinion is not considered an
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saw their device as being targeted at home market,
acknowledged that the patient user is becoming increas-
ingly important, particularly as they are now selling
more directly to the home patient. However, the major-
ity of individuals involved in the MDDD process are still
predominantly senior health professionals as opposed to
patients, who may play a stronger role in the clinical
trials phase, after the device has been designed and
developed. Therefore, the role of the patient user is con-
sidered to play a passive role, more in terms of verifying
the value of an already developed device, as opposed to
being involved in the initial design and development
stages. This is discussed in more detail in the next
section.
Another factor discouraging manufacturers from
involving patient users in the MDDD process is the pro-
spect of having to obtain ethical approval in order to
carry out the research. When asked whether there are
any difficulties in obtaining ethical approval for invol-
ving patient users in the MDDD process, Manufacturer
#3 stated:
#3: “Yes. A huge problem. In my experience if you are
not affecting patient care, patient throughput, you
can get ‘ethics’, but if you are you won’t get it, or you
might but it will take years. So you have to design
your trial so as not to affect patient care.”
Manufacturer #1 also comments on the ethical
approval process and the R&D committees that must be
attended to when employing more formal methods
users, both patient users and professional users in the
collection of clinical data.
#1:R & Dc o m m i t t e e s .T h a t ’s another thing. You start
a study and surgeon wants to collect clinical data to
be sure that they want to use this. Their experience
that this is the product they want to use. You have to
notify the hospital R&D and then suddenly they see it
as an R&D project, so they throw on their overheads
and it’s an extra hurdle to go through. They start
reviewing it in addition to ethical board. This is
what has changed in the last few years. In those days
you notified the larger University hospitals. Increas-
ingly has to be approved. Some are straightforward;
others ask extra questions that delays process - UK
research.
This perceived difficulty with obtaining ethical
a p p r o v a lm a yb eo n er e a s o nw h ym a n u f a c t u r e r st e n d
not to use formal methods, or engage in systematic
research activity in order to inform the MDDD process,
particularly at the early stages of development. Indeed
manufacturers appear to actively avoid involving profes-
sional and patient users in the process, in fear that the
MDDD process could be delayed for years as a result of
the ethical approval process. As identified in section 3.2,
informal discussion with clinical staff is seen as a more
realistic, pragmatic, and feasible route to informing the
MDDD process, which can be carried out informally
and hence without ethical clearance. Manufacturer #3
goes on to describe the strategy that they use to get
around the challenge of obtaining ethical approval:
#3: “So you take the least hard route, to not affect
patient care in any way whatsoever, and design your
study to sit on the back of that. So the study might
not be optimal, but at least you can do it.”
Setting up device design and development activity so as
to avoid the need for user involvement seems to be the
‘method’ of choice for some device manufacturers. Despite
this being seen as a potentially sub-optimal approach, per-
haps less effective in evaluating the extent to which design
innovations may be accepted by users, it seems a route
worth taking given the alternative of incurring long delays
as a result of the ethical approval process.
The nature of user contributions
The measures used to evaluate the effectiveness of newly
developed devices towards the end of the MDDD process
echo the findings presented earlier, that formal methods
employed in any part of the MDDD process are seen by
manufacturers as having the potential of slowing the process
down, and incurring additional and unnecessary costs and
overheads that otherwise could be avoided if a less formal
approach was taken. Most commonly, manufacturers
reported that the success of a new device is typically mea-
sured by the absence of receiving customer complaints or
‘bad news’ emerging as a result of the device being used in
the field. Manufacturer #1, in response to being asked how
the success of their device is measured responded as follows:
#1: “The absence of bad news. The fact that we have
access to the surgeons who are using the product and
any adverse effects would be reported and we would
be aware early on.”
With regards to seeking patient feedback about the suc-
cess of a medical device in providing an effective health
intervention, Manufacturer #3 takes a similar ‘no bad
news is good news’ approach to the design and function-
ing of their product. When asked whether any patient
feedback is sought about the device, the reply was:
#3: “Not explicitly, we haven’t gone out to get it, but
we get feedback though the users (clinicians). It’s
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not a problem to use it. No-one has said they don’t
want it done or had any problems with that.”
Manufacturer #9, commenting on whether any formal
methods are used for converting user needs into device
design requirements, also indicated that they adopt a
reactive stance to customer suggestions and complaints,
which is their default position on such matters.
#9: “Erm, we certainly have regular meetings here
where we will look at customer feedback, you know,
whether it’s customer complaints or customer sugges-
t i o n so rw h a t e v e r ,y e ss o ,y e sw ed oh a v eam e a n st o
do that...”
Some evidence of formal user involvement did emerge
from the interview data, however, it indicated that the
majority of formal user involvement took place at the
clinical trials stage, i.e. after the product had been devel-
oped, and manufacturers were at the stage of demon-
strating its efficacy and clinically effectiveness.
Therefore, in effect any considerations in terms of
design preference of the medical device that may benefit
the user in terms of their treatment or use of the device
had already been made prior to this formal user involve-
ment. Manufacturer #2 highlights the notion that the
patient user is primarily seen as being of value when
attempting to demonstrate the clinical effectiveness of a
new medical device.. Interestingly, patient users are not
seen as primarily informing the general design of the
device at earlier stages of the MDDD process, at least
not in a formal capacity. When asked whether formal
user methods are employed within the MDDD process,
Manufacturer #2 responded:
#2: “There is the formal method of gaining patient
data which means at the moment for example we
have conducted clinical trials, clinical investigations.
All sorts of clinical information gathering is going on
at the [hospital name]. We are also... we tend to
gather information first of all on the effectiveness or
efficacy of it...Any advance, any variation that is
likely to happen to the unit, any proposals for change
that are going to improve the machine are all tested
out in the clinical environment.”
Manufacturer #5 reported that the key driver for col-
lecting formal user data, relating to the performance of
a device, comes from the possibility that an organisation
such as the National Institute for Clinical Excellence
(NICE) may decide to investigate the efficacy of their
device at some unknown point. Therefore, the key driver
for formally collecting user generated data is to fulfil the
potential future requirements of external standards or
purchasing agencies. The motivation to collect user
facing data does not appear to be borne out of an inher-
ent belief, on the manufacturer’s behalf, that this user
data would add any significant value in terms of fulfill-
ing their own need to develop more effective devices or
indeed learn more about the effectiveness and efficiency
of their own device.
#5: I think, if you take an organisation like NICE as
a customer, or any of the other health technology
organisations, one doesn’tk n o ww h e t h e ry o u rp a r t i -
cular intervention is going to be assessed by them,
and if so at what point, and one can see that as [the
product] gains momentum and the NHS starts to
look at what its spending on [this] surgery, then it
may be something that NICE feel, or NICE get direc-
ted to take a look at. So it’sak i n do fap r o b l e mt o
us to understand when that’s going to happen and it
will certainly be a challenge; we have to therefore
make sure that we are gathering the evidence in case
they do.”
Discussion and Conclusions
In this study, 11in-depth interviews were carried out
with medical device manufacturers, who were asked to
comment on the role and value they believed that users
have within the MDDD process. Given the small sample
size, it is recognised that the results of this study should
be considered as provisional. However, given the limited
existing research in this area, the findings provide an
important point of reference for further work.
The results revealed that manufacturers tend to priori-
tise the views of more senior health professionals above
those that are less senior as well as patients. Furthermore,
manufacturers’ perceptions of the customer and the user
has become conflated, partly due to the strong sales
focus of manufacturers, seeking device design input from
those individuals who make purchasing decisions, as
opposed to the users of the devices. With regards to seek-
ing input from the patient user, there was little motiva-
tion to engage in such practice which was seen as an
ineffective use of resources, with patients, and less senior
health professionals being perceived as having little
impact or influence on general device sales, largely due
to the inbuilt culture of patients being ‘taught down’
their needs from health care professionals.
Only one out of 11 manufacturers claimed to regularly
use formal user centred design methods within the
MDDD process. Interestingly, this individual also
reported that they were familiar with such methods as a
result of being introduced to them within the university
setting in which they carried out the initial formulation
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experience appeared to have had a lasting effect, as they
report the ongoing use of formal research methods to
this day. It is therefore possible that a contributory fac-
tor to lack of engagement with formal methods is a lack
of education, familiarity or confidence in their use.
Necessary training has indeed been found to be a factor
that affects the level of uptake of usability methods in
medical device development [34]. Informal methods
were typically preferred by manufacturers, in the form
of extemporised discussions with a small number of
esteemed medical experts. There was also a belief that if
a manufacturer wished to be competitive and responsive
within a fast moving market, formal methods do not
offer the necessary versatility and are more generally not
appropriate for purpose, despite the proposed benefits
that academic literature suggests such methods promise
if applied within the health care sector [35,36]. Research
in the technology design domain suggests it is necessary
to adopt a flexible and evolutionary stance when apply-
ing formal methods to cater for the unique context and
organisational cultures that present themselves within
any new design challenge [37]. Similarly, there may be
value in increasing awareness of the versatility of exist-
ing human factors engineering methods, and in specia-
list contexts to explore the potential development of
more agile and tailored methods that cater for manufac-
turers’ needs in the context in which they are to be
applied. It has been suggested that, as a consequence of
the increased pressure from standards agencies to incor-
porate formal user methods into the MDDD process,
some manufacturers may ‘misuse’ existing human fac-
tors methods [38]. The reasons for this are unclear. Is it
perhaps in a bid to make methods more fit for purpose,
or as a result of not being fully aware of the ways in
which existing methods should be applied?
The perceived barriers to user involvement within the
MDDD process were linked to the notion that manufac-
turers seek out those individuals that will be most influen-
tial in making purchasing decisions for their products.
Consequently, involving patient users appeared to be of
lowest priority, since it was believed that they held the
lowest level of influence over whether health care organi-
sations purchased their products. These findings are sup-
ported by our earlier preliminary work relating to barriers
to user involvement [39,40]. The examples that did emerge
of consulting users via formal methods, tended to occur at
the end of the MDDD process, after the device had been
designed and developed, where users played a passive role
in aiding the manufacturer in verifying the efficacy of the
device primarily for the purposes of satisfying external
standards and purchasing agencies requirements. One key
r e a s o nf o ra v o i d i n gu s e ri n v olvement was the difficulty
that this presents when attempting to gain ethical approval
for user elicitation studies. Manufacturers conceded that,
although avoiding user involvement may perhaps be sub-
optimal, it is necessary if they are to remain competitive
within a fast moving market. Warlow [41] and Stewart
et al. [42] both propose that over-regulation of clinical
research poses a significant threat to public health and it
seems that this study support this. In particular, our find-
ings suggest that the seemingly unnecessary bureaucracy
associated with obtaining ethical approval for non-inter-
ventional and low-risk studies, that seek to capture user
opinions and requirements, leads to manufacturers
excluding the voice of the user from the development
process.
This study reveals that the notion of proactively invol-
ving the user within the MDDD process in general
slows down the process. Rather, a reactive ‘no bad news
is good news’ stance is taken, only taking into account
users input if they are presented in the form of com-
plaints or feedback on devices that have already been
released into the health care system. The only evidence
of engagement with formal methods of user involvement
is apparent when the use of such methods are manda-
tory, dictated to manufacturers by standards and pur-
chasing agencies. Given the findings of this study, the
appropriate employment of formal methods by manufac-
turers is unlikely to occur to significant levels without
deliberate efforts to encourage and support manufac-
turers in doing so. The following recommendations pro-
pose where some of these efforts should focus, in order
to achieve increased levels of user engagement by manu-
facturers, as is now stipulated by IEC 62366 [14]:
- Research to better understand the requirements of
manufacturers, in terms what is required from
human factors engineering methods in order to
make their use more feasible and accessible in
practice.
- Provision of training on the use and benefits of
employing formal human factors engineering meth-
ods at every stage of the MDDD process.
- Health care providers should implement formal
processes to ensure better communication and
synergy between those making purchasing decisions
and the actual users of the devices.
- Provisions should be made within the ethical
approval process that enables medical device manu-
facturers to engage more easily with users with mini-
mal levels of bureaucracy whilst also ensuring that
all research is conducted in an ethical manner that
protects healthcare staff and patients.
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